Please assess the completion status of the following clinical trial:

Trial Title: Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Current or former smoker who has smoked ≥ 30 pack-years (i.e., 1 pack per day for ≥ 30 years)~  * A former smoker is defined as one who has stopped smoking for ≥ 1 year~* C-reactive protein level \> 1.2 mg/L~* One or more areas of dysplasia with a surface diameter \> 1.2 mm on autofluorescence bronchoscopy~* No carcinoma in situ or invasive cancer on bronchoscopy~* No abnormal spiral chest CT scan suspicious of lung cancer~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Willing to take Polyphenon E or placebo twice a day regularly~* Willing to undergo bronchoscopy and spiral chest CT scan~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Creatinine normal~* Bilirubin normal~* AST and ALT normal~* Alkaline phosphatase normal~* No chronic active hepatitis or liver cirrhosis~* No severe heart disease (e.g., unstable angina or chronic congestive heart failure)~* No ongoing gastric ulcer~* No acute bronchitis or pneumonia within the past month~* No known reaction to xylocaine, salbutamol, midazolam, or alfentanil~* No known allergy to green tea and/or corn starch, gelatin, or other nonmedicinal ingredients~* No medical condition, such as acute or chronic respiratory failure or bleeding disorder, that, in the opinion of the investigator, could jeopardize patient safety during study participation~PRIOR CONCURRENT THERAPY:~* No concurrent consumption of \> 7 cups of tea a week~* No other concurrent natural health products containing green tea compounds~* No concurrent antiarrhythmic agents~* No concurrent anticoagulants, such as warfarin or heparin

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive oral Polyphenon E twice daily for 3 months in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: PLACEBO_COMPARATOR): Patients receive a placebo twice daily for 3 months in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).